{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:52:07Z","timestamp":1786996327221,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.rmr.2019.12.005","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T07:44:52Z","timestamp":1586331892000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ototoxicit\u00e9 li\u00e9e \u00e0 la kanamycine au cours du traitement de la tuberculose multir\u00e9sistante"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-4361","authenticated-orcid":false,"given":"V.","family":"Poka-Mayap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Balkissou Adamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.W.","family":"Pefura-Yone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kuaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2019.12.005_bib0105","series-title":"Global Tuberculosis Report 2017","first-page":"1","year":"2017"},{"key":"10.1016\/j.rmr.2019.12.005_bib0110","series-title":"Principes directeurs \u00e0 l\u2019intention des programmes antituberculeux pour la prise en charge des tuberculoses pharmacor\u00e9sistantes","year":"2009"},{"key":"10.1016\/j.rmr.2019.12.005_bib0115","series-title":"Guidelines for clinical and operational management of drug-resistant tuberculosis","author":"Perrin","year":"2013"},{"key":"10.1016\/j.rmr.2019.12.005_bib0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","article-title":"Aminoglycoside-induced ototoxicity","volume":"13","author":"Selimoglu","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.rmr.2019.12.005_bib0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijtb.2016.01.031","article-title":"Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis","volume":"63","author":"Prasad","year":"2016","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.rmr.2019.12.005_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmr.2019.12.005_bib0135","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/sajcd.v63i1.154","article-title":"An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal","volume":"63","author":"Appana","year":"2016","journal-title":"South African J Commun Disord"},{"key":"10.1016\/j.rmr.2019.12.005_bib0140","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1183\/09031936.00044812","article-title":"Hearing loss in patients on treatment for drug-resistant tuberculosis","volume":"40","author":"Seddon","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2019.12.005_bib0145","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice","volume":"66","author":"Sturdy","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2019.12.005_bib0150","doi-asserted-by":"crossref","first-page":"e000411","DOI":"10.1136\/bmjopen-2011-000411","article-title":"Hearing in 44\u201345\u00a0year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study","volume":"2","author":"Rahman","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2019.12.005_bib0155","series-title":"Classification audiom\u00e9trique des d\u00e9ficiences auditives","author":"Bureau International","year":"2000"},{"key":"10.1016\/j.rmr.2019.12.005_bib0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmr.2019.12.005_bib0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.anl.2016.10.005","article-title":"Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy","volume":"44","author":"Sogebi","year":"2017","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.rmr.2019.12.005_bib0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6815-7-5","article-title":"Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up","volume":"12","author":"Duggal","year":"2007","journal-title":"BMC Ear Nose Throat Disord"},{"key":"10.1016\/j.rmr.2019.12.005_bib0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40360-015-0036-7","article-title":"Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort","volume":"16","author":"Sagwa","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rmr.2019.12.005_bib0180","series-title":"Audiologic management of individuals receiving cochleotoxic drug therapy","author":"American Speech-Language-Hearing Association","year":"1994"},{"key":"10.1016\/j.rmr.2019.12.005_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1755-7682-5-3","article-title":"Cochleo-vestibular clinical findings among drug resistant tuberculosis patients on therapy \u2013 A Pilot Study","volume":"5","author":"Ramma","year":"2012","journal-title":"Int Arch Med"},{"key":"10.1016\/j.rmr.2019.12.005_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BJMMR\/2016\/24421","article-title":"Vestibulo-otologic events in drug-resistant tuberculosis patients on medications","volume":"14","author":"Sogebi","year":"2016","journal-title":"Br J Med Res"},{"key":"10.1016\/j.rmr.2019.12.005_bib0195","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"10.1016\/j.rmr.2019.12.005_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/AAC.01400-16","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","volume":"61","author":"van Altena","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842520300310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842520300310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:55Z","timestamp":1760105995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842520300310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0761842520300310"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2019.12.005","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ototoxicit\u00e9 li\u00e9e \u00e0 la kanamycine au cours du traitement de la tuberculose multir\u00e9sistante","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}